Published in Expert Opin Pharmacother on June 12, 2015
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | NCT01685268
Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer | NCT01867333
XL-184+Abiraterone in Post-Chemo CRPC | NCT01574937
AMG 386 and Abiraterone for Advanced Prostate Cancer | NCT01553188
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer | NCT02012920
Sequencing Abiraterone and Enzalutamide in mCRPC | NCT02125357
A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer | NCT01647789
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer | NCT02407054
BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) | NCT02204072
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. Clin Med Insights Oncol (2016) 0.83
Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity. Mol Cancer Ther (2016) 0.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med (2014) 12.29
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol (1993) 6.55
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res (2012) 5.50
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature (2014) 5.45
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest (2008) 4.13
Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet (2010) 3.83
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife (2013) 3.49
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol (2014) 3.10
Tumor clone dynamics in lethal prostate cancer. Sci Transl Med (2014) 2.93
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol (2013) 2.87
A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov (2013) 2.87
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 2.81
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci Transl Med (2015) 2.55
The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur Urol (2014) 2.52
An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov (2013) 2.52
Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol (2013) 2.38
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol (2015) 2.32
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res (2015) 2.12
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol (2012) 2.07
The androgen receptor gene mutations database: 2012 update. Hum Mutat (2012) 1.84
NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther (2013) 1.81
Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol (2014) 1.79
An androgen receptor N-terminal domain antagonist for treating prostate cancer. J Clin Invest (2013) 1.64
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59
Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res (2014) 1.51
Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res (2009) 1.41
Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther (2011) 1.39
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol (2013) 1.38
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res (2014) 1.27
Regulation of the androgen receptor by post-translational modifications. J Endocrinol (2012) 1.27
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer (2007) 1.23
Transcription-induced DNA double strand breaks: both oncogenic force and potential therapeutic target? Clin Cancer Res (2011) 1.21
High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol (1998) 1.20
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget (2013) 1.17
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). Eur Urol (2013) 1.15
Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res (2007) 1.12
Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 1.11
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int (2012) 1.07
Androgen receptor: structural domains and functional dynamics after ligand-receptor interaction. Ann N Y Acad Sci (2001) 1.06
The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate (2012) 1.01
Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer. BJU Int (2001) 1.01
Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In Vivo (2004) 0.96
Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. Am J Pathol (2014) 0.94
N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Mol Oncol (2014) 0.94
Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int J Cancer (2011) 0.93
A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer (2013) 0.93
The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One (2012) 0.92
Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel. Value Health (2015) 0.91
Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key? Expert Rev Anticancer Ther (2014) 0.89
Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer. J Clin Invest (2014) 0.88
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate (2014) 0.88
Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer (2012) 0.82
A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer. Br J Cancer (2013) 0.81
Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells. Anticancer Res (2014) 0.79
Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC). Cancer Chemother Pharmacol (2013) 0.76
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Expanding treatment options for metastatic prostate cancer. N Engl J Med (2011) 2.39
Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol (2015) 1.90
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol (2013) 1.22
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer (2011) 1.20
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther (2011) 1.14
Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer (2014) 1.11
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clin Cancer Res (2010) 1.05
A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urol Oncol (2011) 0.99
Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl (2012) 0.98
Clinical problem-solving. Beware of first impressions. N Engl J Med (2008) 0.97
Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. Cancer Lett (2012) 0.95
Tumorigenic potential of circulating prostate tumor cells. Oncotarget (2013) 0.94
Growth factor and signaling pathways and their relevance to prostate cancer therapeutics. Cancer Metastasis Rev (2014) 0.92
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate (2014) 0.92
Management of patients with biochemical recurrence after local therapy for prostate cancer. Hematol Oncol Clin North Am (2013) 0.92
Surgical resection of malignant melanoma metastatic to the pancreas: case series and review of literature. J Gastrointest Cancer (2012) 0.90
Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Int J Mol Sci (2013) 0.89
Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate (2014) 0.88
Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences. J Clin Oncol (2013) 0.87
Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. Hum Vaccin Immunother (2012) 0.86
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate (2011) 0.84
Prostate angiosarcoma: a case report and literature review. Med Oncol (2012) 0.83
Prostate angiosarcoma: is there any association with previous radiation therapy? BJU Int (2012) 0.82
Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid (2013) 0.82
Update: immunological strategies for prostate cancer. Curr Urol Rep (2010) 0.82
A pilot phase II Study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA. Am J Cancer Ther Pharmacol (2014) 0.82
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate (2011) 0.81
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis. Oncology (Williston Park) (2014) 0.81
Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol (2012) 0.81
Resistance to androgen-pathway drugs in prostate cancer. N Engl J Med (2014) 0.80
Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer. Clin Genitourin Cancer (2013) 0.79
Rheumatoid arthritis masked by docetaxel chemotherapy in a patient with ovarian carcinoma. J Clin Rheumatol (2008) 0.78
Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol (2012) 0.77
Abiraterone acetate: a hat trick of clinical benefits. Lancet Oncol (2012) 0.76
Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. Curr Opin Endocrinol Diabetes Obes (2016) 0.76
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer. Urol Clin North Am (2012) 0.75
The unfolding treatment landscape for men with castration-resistant prostate cancer. Clin Investig (Lond) (2011) 0.75
Abiraterone for the Treatment of Advanced Prostate Cancer. Int J Target Ther Cancer (2012) 0.75
Acute psychological stress-induced water intoxication. Int J Psychiatry Clin Pract (2005) 0.75
A cut above. Am J Med (2007) 0.75